Telavancin
WikiDoc Resources for Telavancin |
Articles |
---|
Most recent articles on Telavancin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Telavancin at Clinical Trials.gov Clinical Trials on Telavancin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Telavancin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Telavancin Discussion groups on Telavancin Patient Handouts on Telavancin Directions to Hospitals Treating Telavancin Risk calculators and risk factors for Telavancin
|
Healthcare Provider Resources |
Causes & Risk Factors for Telavancin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Telavancin is a bactericidal lipoglycopeptide under trial for use in MRSA or other Gram-positive infections.
On October 19, 2007, the US Food and Drug Administration issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008. [1]
References
- ↑ "Drugs.com, FDA Accepts for Review Response to Approvable Letter for Telavancin". Retrieved 2008-03-08.